Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a2ee3e16eccc4c4487381ac1367b8191 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a2ee3e16eccc4c4487381ac1367b81912021-11-25T05:59:38ZAccurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.1932-620310.1371/journal.pone.0107200https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b81912014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0107200https://doaj.org/toc/1932-6203<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation prompted us to investigate two ALK IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an automated ALK FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples.<h4>Methods</h4>Forty-seven ALK FISH-positive and 56 ALK FISH-negative NSCLC samples were studied. All specimens were screened for ALK expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for ALK rearrangement by FISH (Vysis ALK FISH break-apart kit), which was automatically captured and scored by using Bioview's automated scanning system.<h4>Results</h4>All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively.<h4>Conclusions</h4>The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations.Esther CondeAna Suárez-GauthierAmparo BenitoPilar GarridoRosario García-CampeloMichele BiscuolaLuis Paz-AresDavid HardissonJavier de CastroM Carmen CamachoDelvys Rodriguez-AbreuIhab AbdulkaderJosep RamirezNoemí ReguartMarta SalidoLara PijuánEdurne ArriolaJulián SanzVictoria FolguerasNoemí VillanuevaJavier Gómez-RománManuel HidalgoFernando López-RíosPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 9, p e107200 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Esther Conde Ana Suárez-Gauthier Amparo Benito Pilar Garrido Rosario García-Campelo Michele Biscuola Luis Paz-Ares David Hardisson Javier de Castro M Carmen Camacho Delvys Rodriguez-Abreu Ihab Abdulkader Josep Ramirez Noemí Reguart Marta Salido Lara Pijuán Edurne Arriola Julián Sanz Victoria Folgueras Noemí Villanueva Javier Gómez-Román Manuel Hidalgo Fernando López-Ríos Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| description |
<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation prompted us to investigate two ALK IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an automated ALK FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples.<h4>Methods</h4>Forty-seven ALK FISH-positive and 56 ALK FISH-negative NSCLC samples were studied. All specimens were screened for ALK expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for ALK rearrangement by FISH (Vysis ALK FISH break-apart kit), which was automatically captured and scored by using Bioview's automated scanning system.<h4>Results</h4>All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively.<h4>Conclusions</h4>The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations. |
| format |
article |
| author |
Esther Conde Ana Suárez-Gauthier Amparo Benito Pilar Garrido Rosario García-Campelo Michele Biscuola Luis Paz-Ares David Hardisson Javier de Castro M Carmen Camacho Delvys Rodriguez-Abreu Ihab Abdulkader Josep Ramirez Noemí Reguart Marta Salido Lara Pijuán Edurne Arriola Julián Sanz Victoria Folgueras Noemí Villanueva Javier Gómez-Román Manuel Hidalgo Fernando López-Ríos |
| author_facet |
Esther Conde Ana Suárez-Gauthier Amparo Benito Pilar Garrido Rosario García-Campelo Michele Biscuola Luis Paz-Ares David Hardisson Javier de Castro M Carmen Camacho Delvys Rodriguez-Abreu Ihab Abdulkader Josep Ramirez Noemí Reguart Marta Salido Lara Pijuán Edurne Arriola Julián Sanz Victoria Folgueras Noemí Villanueva Javier Gómez-Román Manuel Hidalgo Fernando López-Ríos |
| author_sort |
Esther Conde |
| title |
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| title_short |
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| title_full |
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| title_fullStr |
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| title_full_unstemmed |
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| title_sort |
accurate identification of alk positive lung carcinoma patients: novel fda-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191 |
| work_keys_str_mv |
AT estherconde accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT anasuarezgauthier accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT amparobenito accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT pilargarrido accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT rosariogarciacampelo accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT michelebiscuola accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT luispazares accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT davidhardisson accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT javierdecastro accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT mcarmencamacho accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT delvysrodriguezabreu accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT ihababdulkader accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT josepramirez accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT noemireguart accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT martasalido accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT larapijuan accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT edurnearriola accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT juliansanz accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT victoriafolgueras accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT noemivillanueva accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT javiergomezroman accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT manuelhidalgo accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry AT fernandolopezrios accurateidentificationofalkpositivelungcarcinomapatientsnovelfdaclearedautomatedfluorescenceinsituhybridizationscanningsystemandultrasensitiveimmunohistochemistry |
| _version_ |
1718414298263322624 |